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in primary tissue culture by, 699 
positive feedback of, in L H - and a-subunit-
secreting pituitary tumor, 692 
preovulatory follicular biosynthesis of, con-
trol in the human ovary, 847 
receptor, concentrations in the endome-
trium of postmenopausal women on es-
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trogen replacement therapy, cyclic 
clomiphene citrate-induced lowering 
of, 345 
site of inhibition of gonadotropins by, stud-
ies in rhesus monkeys, delivery of 11 ß -
estradiol to the hypothalamus and pi-
tuitary gland, 1 
stimulation of neurophysin, correlation 
with oxytocin in human plasma, 988 
synthetic, modulation of the progesterone 
receptor level in human endometrial 
cells in primary tissue culture by, 699 
Estrone 
binding in endometrium at implantation, 
changing ratios of estradiol binding to, 
regulation by hCG and progesterone 
during rescue of the primate corpus 
luteum, 133 
plasma levels in postmenopausal women 
after Premarin administration, RIA of, 
741 
Euglycemia, impact on stimulated pituitary 
hormone release in insulin-dependent 
diabetics, 1230 
Exercise 
graded, effect of fasting on the hormonal 
response to in men, 1106 
responses of PRL, GH, TSH, T 3 , and T 4 to, 
after fat- and carbohydrate-enriched 
diets, 56 
Fasting, effect on the hormonal response to 
graded exercise in men, 1106 
Fat, -enriched diet, responses of PRL, GH, 
TSH, T 3 , and T 4 to exercise after, 56 
Fetus 
age-related changes during early and mid-
pregnancy in endogenous steroids of 
the testis in, 98 
immunocytological evidence for PTH in the 
parathyroid gland of, 513 
PRL transport by membranes in, 220 
role of cAMP in cholesterol metabolism and 
steroidogenesis by the human adrenal 
in, 1124 
the major immunoreactive aMSH-like sub-
stance in pituitary tissue of, 319 
Fibroadenoma, of the breast, estradiol and 
progesterone receptors in, 1225 
Follicle-stimulating hormone (FSH) 
abnormal patterns of, contrasting with nor-
mal estradiol and progesterone secre-
tion in women with long-standing 
unexplained infertility, 1218 
-dependent folliculogenesis during the pri-
mate ovarian cycle, suppression of, 451 
inverse relation between seminal plasma 
inhibin and, 796 
secretion in children, effect of a-bromoer-
gocriptine on, 314 
Follicular fluid 
inhibin F activity in, relationship between 
steroid content of follicular fluid and, 
1193 
steroid content of, relationship between in-
hibin F activity in follicular fluid and, 
1193 
Galactorrhea, composition of breast fluid of a 
man with, 581 
Gastric inhibitory polypeptide 
hypersecretion in diabetes mellitus, effect 
of sulfonylurea treatment, 1002 
role in mediating discrepant performance 
on oral and iv glucose tolerance tests, 
1199 
Germinoma (pinealoma), of the central ner-
vous system, in children and adoles-
cents, effect of therapy on hormonal 
and metabolic abnormalities associated 
with, 9 
Glucagon 
antibodies to, in insulin-treated diabetics, 
948 
effect on pathogenesis of stress hypergly-
cemia, 1235 
elevated plasma levels in patients with my-
otonic dystrophy, 790 
yß-endorphin-stimulated secretion of, 592 
plasma levels, response to insulin-induced 
hypoglycemia in healthy subjects, 477 
Glucocorticoid 
effect on the insulin receptor, 953 
lack of effect on dopaminergic modulation 
of aldosterone secretion, 1078 
short term administration of, effects on in-
testinal calcium absorption and circu-
lating vitamin D metabolite concentra-
tions, 111 
Glucose 
blood levels in patients with insulinoma, 
lack of effect of calcium infusion on, 
804 
clinical significance of altered insulin sen-
sitivity in diabetes mellitus assessed by 
infusion of, 982 
counterregulatory hormones during mod-
erate insulin-induced decrements in 
blood levels of, 477 
production, suppression by physiological 
concentrations of ketone bodies, 34 
role of gastric inhibitory polypeptide in the 
discrepant performance on oral and iv 
tolerance tests for, 1199 
Goiter, congenital, and the development of 
metastatic follicular carcinoma with 
evidence for a leak of nonhormonal 
iodide, 294 
Gonad, autoantibodies of, in patients with 
hypogoadism and/or Addison's dis-
ease, 1137 
Gonadotroph, increased responsivity of, in hy-
perprolactinemic women with pituitary 
PRL-secreting adenomas, 1171 
Gonadotropin 
failure of therapy with in Kallmann's syn-
drome, secondary to hCG-induced 
antibodies, 929 
human anti-LRH antibodies in the serum 
of a patient with deficiency of, after 
treatment with synthetic LRH, 267 
human chorionic (hCG) 
-induced antibodies, gonadotropin ther-
apy failure secondary to, 929 
-like substance in the plasma of normal 
men, lack of modulation by GnRH, 
1249 
regulation of the changing ratios of nu-
clear estrone to estradiol binding in 
endometrium at implantation by, dur-
ing rescue of the primate corpus lu-
teum, 133 
stimulation of cAMP and sex steroids in 
the spermatic venous blood by injec-
tion into human testes of, 688 
inappropriate secretion in .women with pol-
ycystic ovarian disease, elevations in 
unbound serum estradiol as a possible 
mechanism for, 156 
isolated deficiency of, failure of therapeutic 
response to long term therapy with 
L R H in, 557 
aMSH-induced release of, 159 
pituitary, secretion in postmenopausal fe-
males, down-regulation by continuous 
GnRH administration, 171 
pituitary secretion of, recovery after preg-
nancy termination, 545 
plasma and urinary levels, interrelationship 
of, correlations for 24 h, for sleep/wake 
periods, and for 3 h after L R H stimu-
lation, 225 
serum levels, in full-term and premature 
infants, 235 
studies in rhesus monkeys on the site of 
estrogen inhibition of, delivery of 11 ß -
estradiol to the hypothalamus and pi-
tuitary gland, 1 
suppression of with A9-tetrahydrocannabi-
nol in rhesus monkeys, effects on the 
follicular phase of the menstrual cycle, 
50 
Gonadotropin-releasing hormone (GnRH) 
down-regulation of pituitary gonadotropin 
secretion in postmenopausal females 
by continuous administration of, 171 
effect on pituitary hormone release in dia-
betes mellitus, impact of euglycemia 
and hyperglycemia on, 1230 
increased L H and FSH responses to, in 
hyperprolactinemic women with pitui-
tary adenomas, 1171 
lack of modulation of the hCG-like sub-
stance in the plasma of normal men, 
1249 
Gonads, hormones of, plasma levels in women 
during lactation, 678 
Graves' disease 
development and evaluation of a method 
for the partial purification of immuno-
globulins specific for, 1113 
enhanced conversion of T 3 from T 4 in the 
thyroid of patients with, 1211 
patterns of change in the early radioiodine 
uptake during Carbimazole treatment 
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Graves' disease (continued) 
of, relationship to outcome, 1067 
suppressor T-lymphocyte deficiency in, 528 
T-lymphocyte sensitization in, confirmed 
by an indirect migration inhibition fac-
tor test, 523 
Growth, in transient neonatal diabetes melli-
tus, 144 
Growth hormone (GH) 
acute somatomedin response to, RIA vs. 
radioreceptor assay, 616 
effect of exogenous /^ -endorphin on pitui-
tary release of, 1179 
effect on metaphyseal uptake of the 9 9 m T c -
methylene diphosphonate, in GH-defi-
cient children, 1162 
effects of treatment with on somatomedin 
receptor sites in hypopituitary children 
of treatment with, 759 
human, platelet growth factor in children 
deficient in, 128 
piperidine enhancement of sleep-related 
and insulin-induced secretion of, evi-
dence for a cholinergic secretory mech-
anism, 409 
plasma levels 
responses to the synthetic enkephalin an-
alog (FK 33-824) in normal subjects 
and patients with pituitary diseases, 
263 
response to insulin-induced hypoglyce-
mia in healthy subjects, 477 
response to arginine infusions in hypothy-
roid patients, effect of T 3 or T R H on, 
86 
response to exercise after fat- and carbo-
hydrate-enriched diets, 56 
response to insulin-induced hypoglycemia, 
effect of dopaminergic blockade on, 807 
response to T R H during R E M and slow 
wave sleep, 975 
response to T R H in diabetes, 859 
secretion in children, effect of a-bromoer-
gocriptine on, 314 
secretory status, as a determinant of the 
TSH response to T R H in euthyroid 
patients with hypothalamic-pituitary 
disease, 324 
temporal relationship of decreased serum 
somatomedin C concentrations during 
sleep to nocturnal surges of, 399 
Hashimoto's disease, human T-lymphocyte 
subpopulations in, 553 
Hashimoto's thyroiditis 
suppressor T-lymphocyte deficiency in, 528 
T-lymphocyte sensitization in, confirmed 
by an indirect migration inhibition fac-
tor test, 523 
Heart, cardiac failure, potency of angiotensin 
II and potassium in regulating aldoste-
rone in, during Captopril therapy, 1253 
Hemiaplasia, of the thyroid, with thyrotoxi-
cosis, 152 
Hemoglobin Ai c, repetitive determination in 
diabetic out-patients of levels of, 1019 
Hermaphroditism, true, with male phenotype, 
induction of ovulation in, 1257 
Histamine 
effect on PRL and L H release, sex differ-
ences and the role of stress, 924 
H 2 receptor, role in PTH secretion in nor-
mal man and in primary hyperparathy-
roidism, 122 
6ß-Hydroxy Cortisol, a noninvasive indicator 
of enzyme induction, 381 
17a-Hydroxylase, deficiency syndrome, ste-
roid excretion in urine during suppres-
sion and stimulation of adrenals in, 37 
21-Hydroxylase, activity in the glomerulosa 
and fasciculata of the adrenal cortex in 
congenital adrenal hyperplasia, 534 
17-Hydroxyprogesterone, concentrations in 
human amniotic fluid throughout ges-
tation, 385 
17/?-Hydroxysteroid dehydrogenase, endome-
trial activity, influence on the binding 
of estradiol to receptors, 252 
Hyperaldosteronism, idiopathic, plasma al-
dosterone response to angiotensin II 
infusion in, 195 
Hypercalcemia 
familial hypocalciuric, vs. typical primary 
hyperparathyroidism, maximal urine-
concentrating ability in, 736 
of malignancy, urinary and nephrogenic 
cAMP in, 765 
Hypercalciuria, idiopathic, influence of cal-
cium intake and absorption status on 
the diagnostic utility of measurements 
of 24-h cAMP excretion in, 1085 
Hyperglucagonemia, in myotonic dystrophy, 
790 
Hyperglycemia 
impact on stimulated pituitary hormone 
release in insulin-dependent diabetics, 
1230 
stress-induced, in humans, synergistic inter-
actions among antiinsulin hormones in 
the pathogenesis of, 1235 
Hyperinsulinism, plasma somatomedin levels 
in children with, 748 
Hyperparathyroidism 
persistent, parathyroid imaging after in-
traarterial injection of selenomethio-
nine in, 83 
primary 
influence of calcium intake and absorp-
tion status on the diagnostic utility of 
measurements of 24-h cAMP excretion 
in, 1085 
role of histamine H2 receptors in PTH 
secretion in patients with, 122 
vs. familial hypocalciuric hypercalcemia, 
maximal urine-concentrating ability in, 
736 
relationship of cAMP accumulation to P T H 
release in dispersed parathyroid tissue 
in, 961 
Hyperplasia 
congenital adrenal, 21-hydroxylase activity 
in the glomerulosa and fasciculata of 
the adrenal cortex in, 534 
testicular Leydig cell, as a cause of familial 
sexual precocity, 271 
Hyperprolactinemia 
associated with increased immunoreactive 
somatomedin C in hypopituitarism, 731 
composition of breast fluid of a man with, 
581 
increased gonadotroph responsivity in 
women with pituitary PRL-secreting 
adenomas and, 1171 
Hypertension 
essential, effect of aging on urinary kalli-
krein excretion in patients with, 1023 
suppression of captopril-induced increases 
in PRA by des-Asp'-Ileu8-angiotensin 
II in, 354 
urinary tetrahydroaldosterone and aldoste-
rone-18-glucuronide excretion in white 
and black patients with, 214 
Hyperthyroidism, MCR and production rates 
of 3^5'-diiodothyronine in comparison 
of infusions using radiolabeled vs. un-
labeled iodothyronine, 722 
Hypoglycemia 
insulin-induced 
effect of dopaminergic blockade on PRL, 
GH, and Cortisol responses to, 807 
effect of truncal vagotomy on the so-
matostatin response to, 823 
peripheral plasma somatostatin-like im-
munoreactive responses to, in healthy 
subjects and in noninsulin-dependent 
maturity-onset diabetics, 330 
Hypogonadism 
cure of, after removal of PRL-secreting ad-
enomas in men, 91 
gonadal autoantibodies in patients with, 
1137 
in a male with an immunologically active, 
biologically inactive L H level, charac-
terization of the abnormal hormone, 
1143 
relationship of androgen to TSH and PRL 
responses to T R H in men with, 173 
Hypoparathyroidism, calcitriol treament of, 
during pregnancy, 810 
Hypophosphatemia, X-linked, effect of calci-
triol on renal handling of phosphate, 
serum phosphate, and bone mineraliza-
tion, 463 
Hypopituitarism 
effects of GH treatment on somatomedin 
receptor sites in children with, 759 
hyperprolactinemia associated with in-
creased immunoreactive somatomedin 
C in, 731 
progressive, hypothalamic atrophy with, in 
an adolescent girl, 562 
Hypothalamus 
delivery of 17/?-estradiol to, in rhesus mon-
keys, 1 
diseased, GH secretory status as a deter-
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minant of the TSH response to T R H 
in euthyroid patients with, 324 
Hypothyroidism 
effect of T 3 or T R H on pituitary hormone 
responses to arginine infusions in pa-
tients with, 86 
elevated levels of circulating carcinoembry-
onic antigen in, 457 
MCR and production rates of 3',5'diiodo-
thyronine in comparison of infusions 
using radiolabeled vs. unlabeled io-
dothyronine, 722 
Immune system, dysfunction of, in patients 
with polyglandular failure syndrome, 
284 
Immunoglobulin 
thyroid-stimulating 
bioassay of, using cultured human thy-
roid cells, 1204 
development and evaluation of a method 
for the partial purification of, from pa-
tients with Graves' disease, 1113 
interaction with soluble TSH receptors 
in fat cells, 665 
Indomethacin, antidiuretic response to in-
jected desmopressin with, 910 
Infertility 
long-standing unexplained, in women, ab-
normal FSH and L H patterns contrast-
ing with normal estradiol and proges-. 
terone secretion in, 1218 
male, inverse relation between seminal 
plasma inhibin and plasma FSH in, 796 
Inhibin, seminal plasma levels, inverse rela-
tion between serum FSH and, 796 
Inhibin F, activity in follicular fluid, relation-
ship between steroid content of follic-
ular fluid and, 1193 
Insulin 
antibodies to, in insulin-treated diabetics, 
948 
binding in human pregnancy, comparisons 
to the postpartum luteal and follicular 
states, 937 
binding to erythrocytes of normal infants, 
children, and adults, variation with age 
and sex, 969 
clinical significance of altered insulin sen-
sitivity in diabetes mellitus assessed by 
infusion of, 982 
clinical significance of altered sensitivity to 
in diabetes mellitus, assessed by glu-
cose, insulin, and somatostatin infu-
sion, 982 
5-day programmed ip delivery to insulin-
dependent diabetic man of, 1165 
degradation in serum of a patient with ap-
parent insulin resistance, 177 
-dependent diabetes, impact of euglycemia 
and hyperglycemia on stimulated pi-
tuitary hormone release in subjects 
with, 1230 
-dependent diabetes mellitus, 5-day pro-
grammed ip insulin delivery in subjects 
with, 1165 
endogenous secretion in transient neonatal 
diabetes mellitus, 144 
/?-endorphin-stimulated secretion of, 592 
-induced blood glucose decrements, coun-
terregulatory hormones during, 477 
-induced GH secretion, enhancement by pi-
peridine, evidence for a cholinergic se-
cretory mechanism, 409 
-induced hypoglycemia 
effect of dopaminergic blockade on PRL, 
GH, and Cortisol responses to, 807 
effect of truncal vagotomy on the so-
matostatin response to, 823 
peripheral plasma somatostatin-like im-
munoreactive responses to, in healthy 
subjects and in noninsulin-dependent 
maturity-onset diabetics, 330 
insulin degradation in serum of a patient 
with apparent resistance to, 177 
plasma levels in patients with insulinoma, 
lack of effect of calcium infusion on, 
804 
receptor 
effect of glucocorticoids in vivo and in 
vitro on, 953 
on monocytes in infants of strictly con-
trolled diabetic mothers, 473 
-receptor interaction in lipoatropic diabe-
tes, heterogeneity of, 416 
resistance to, degradation in serum of a 
nonobese diabetic male with, 177 
secretion, stimulation by physiological con-
centrations of ketone bodies, 34 
Insulinoma, lack of effect of calcium infusion 
on blood glucose and plasma insulin 
levels in patients with, 804 
Insulin receptor 
changes in during oral contraceptive admin-
istration, 29 
solubilized from cultured human fibroblast 
and erythrocyte cell membrane prepa-
rations, characterization of, 17 
Intestine, effects of short term glucocorticoid 
administration on calcium absorption 
by, 111 
Iodide, nonhormonal, congenital goiter and 
the development of metastatic follicu-
lar carcinoma with evidence for a leak 
of, 294 
Iodine 
-deficient pregnant women and their off-
spring, interrelationships between se-
rum T 4 , T 3 , rT 3 , and T S H in, efects of 
iodine supplementation, 671 
effects on interrelationships between serum 
T 4 , T 3 , r T 3 and TSH in iodine-deficient 
pregnant women and their offspring, 
671 
Iodocholesterol 
adrenal uptake, relationship to adrenal zona 
glomerulosa function, 612 
uptake by adrenal tissue and imaging in 
adrenal neoplasms, 1156 
Iodomethylnorcholesterol, adrenal uptake, 
relationship to indices of adrenocorti-
cal function in Cushing's syndrome, 
1062 
Jet lag 
effects on hormonal patterns 
adaptation of melatonin circadian period-
icity, 642 
diruption of pituitary-adrenal periodicity, 
628 
effects on sleep patterns and psychological 
indices, 628 
Kallikrein, urinary excretion in normotensive 
subjects and patients with essential hy-
pertension, effect of aging on, 1023 
Ketone (s), suppression of hepatic glucose pro-
duction and stimulation of insulin se-
cretion by physiological concentrations 
of, 34 
Kidney 
concentrating ability of, in patients with 
familial hypocalciuric hypercalcemia 
and primary hyperparathyroidism, 736 
spurious overestimation of plasma Cortisol 
in patients with chronic failure of, 1242 
vitamin D metabolites and calcium metab-
olism in patients with normal function 
of, 116 
Labor, plasma /^ -endorphin during, 74 
Lactation, oxytocin release and plasma ante-
rior pituitary and gonadal hormones in 
women during, 678 
Leucine-enkephalin-like substance, RIA of, in 
human and canine plasma, 367 
Levonorgestrel, changes in physiologically 
free circulating estradiol and testoster-
one during exposure to, 138 
Ley dig cell(s), hyperplasia, as a cause of fa-
milial sexual precocity, 271 
Liddle's syndrome, effect of triamterene and 
sodium intake on renin, aldosterone, 
and erythorcyte sodium transport in, 
1027 
Lipolysis, in human sc fat cells, effects of 
adenosine on, 359 
Lipoprotein, plasma levels, role in regulation 
of progesterone biosynthesis by human 
corpus luteum tissue in organ culture, 
875 
Lung, small cell cancer of, increased plasma 
and tumor somatostatin-like immuno-
reactivity in, 187 
Luteinizing hormone (LH) 
abnormal patterns of, contrasting with nor-
mal estradiol and progesterone secre-
tion in women with long-standing 
unexplained infertility, 1218 
dopaminergic mechanisms and secretion of, 
differential effects of dopamine and 
bromocriptine on L H release in normal 
women, 650 
effect of exogenous ß-endorphin on pitui-
tary release of, 1179 
effect of histamine and HI and H2 receptors 
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Luteinizing hormone (LH) (continued) 
on the release of, sex differences and 
the role of stress, 924 
endogenous opiate modulation of pulsatile 
release of, 583 
hypogonadism in a male with an immuno-
logically active, biologically inactive 
hormone form of, 1143 
increased sensitivity to dopamine inhibition 
in polycystic ovary syndrome, 231 
L R F agonist-induced pulsatile release of, 
934 
opioid control of, in different pathophysio-
logical states, 1260 
receptor, in human ovarian follicles and 
corpora lutea during the menstrual cy-
cle and pregnancy, 307 
release in normal women, differential ef-
fects of dopamine and bromocriptine 
on, 650 
-secreting pituitary tumor, positive feed-
back of estrogen, 692 
secretion in children, effect of a-bromoer-
gocriptine on, 314 
a-subunit of, -secreting pituitary tumor, 
positive feedback of estrogen, 692 
Luteinizing hormone-releasing factor (LRF), 
long-acting agonist of, simultaneous 
pulsatile release of PRL and L H in-
duced by, 934 
Luteinizing hormone-releasing hormone 
(LRH) 
agonist of, long-acting, pituitary desensiti-
zation with, use in treatment of idio-
pathic precocious puberty, 370 
agonist of (D-Trp 6-LRH), luteolytic effect 
of in rhesus monkeys, 565 
correlation for 24 h of interrelationship of 
plasma and urinary gonadotropins for 
3 h after stimulation by, 225 
effects on concomitant secretion of ACTH, 
^-endorphin, and Y-melanotropin from 
perfused pituitary tumor cells of Cush-
ing's disease, 42 
elevated levels in human milk, 826 
human, antibodies to, in the serum of a 
patient with isolated gonadotropin de-
ficiency treated with synthetic LRH, 
267 
-like material in children, immunoreactive, 
urinary excretion of, correlation with 
pubertal development, 1150 
long term therapy with, in isolated gonad-
otropin deficiency, failure of therapeu-
tic response, 557 
pregnancy after prolonged pulsatile admin-
istration of, in a patient with clomi-
phene-resistant secondary amenor-
rhea, 882 
synthetic, human anti-LRH antibodies in 
the serum of a patient with isolated 
gonadotropin deficiency treated with, 
267 
Lymphocyte 
adenylate cyclase, age-related reduced re-
sponsiveness to isoproterenol of, 863 
insulin receptors on, effect of glucocorti-
coids on, 953 
Malignancy, urinary and nephrogenic cAMP 
in the hypercalcemia of, 765 
Mastectomy, elevated serum PRL levels after, 
148 
Megestrol acetate, medical castration of males 
with, 576 
a-Melanocyte-stimulating hormone, -like sub-
stance, immunoreactive, in human fe-
tal pituitary tissue, 319 
a-Melanocyte-stimulating hormone (aMSH), 
-induced gonadotropin release, 159 
y-Melanotropin, secretion from pituitary tu-
mor cells of Cushing's disease, effects 
of lysine vasopressin, rat median emi-
nence extracts, T R H , and L R H on, 42 
Melatonin, Orcadian periodicity of, effects of 
jet lag on, 642 
Men 
androgen receptors in skin cytosol of, 338 
cure of hypogonadism after removal of 
PRL-secreting adenomas in, 91 
decreased plasma and urinary dopamine 
levels during dietary sodium depletion 
in, 903 
diurnal rhythm of plasma /^endorphin and 
its relationship to sleep stages and 
plasma Cortisol and PRL rhythms in, 
942 
elderly, origin of androstanediol and an-
drostanediol glucuronide in, 772 
/^ -endorphin and other /?-endorphin-immu-
noreactive peptides in the semen of, 
586 
hormonal response to graded exercise in, 
effect of fasting on, 1106 
hypogonadal, relationship of androgen to 
TSH and PRL responses to T R H in, 
173 
hypogonadism with immunologically ac-
tive, biologically inactive L H in, 1143 
infertile, inverse relation between seminal 
plasma inhibin and plasma FSH in, 796 
medical castration with megestrol acetate 
and small doses of diethylstilbestrol of, 
576 
normal 
relationship of androgen to TSH and 
PRL responses to T R H in, 173 
seminal plasma inhibin and plasma FSH 
levels in, 796 
Oligospermie, effects of A'-testolactone on 
the pituitary-testicular axis in, 897 
PRL, GH, T 4 , T 3 , and TSH responses to 
exercise after fat- and carbohydrate-
enriched diets in, 56 
response of plasma PRL to changes in am-
bient temperature and humidity in, 279 
role of histamine H 2 receptors in PTH se-
cretion in, 122 
stimulation of cAMP and sex steroids in 
spermatic venous blood after intrates-
ticular injection of hCG in, 688 
suppression of plasma arginine vasopressin 
levels by isoosmotic central blood vol-
ume expansion in, 256 
with l,2-dibromo-3-chloropropane-induced 
azoospermia, exaggerated P R L re-
sponse to T R H and metoclopramide 
in, 38 
with primary testicular failure, attenuation 
of exaggerated PRL response to T R H 
and metoclopramide in, 289 
young, origin of androstanediol and andros-
tanediol glucuronide in, 772 
Menstrual cycle 
changes in the enzyme activities related to 
steroidogenesis in human ovaries dur-
ing, 994 
L H receptors in human ovarian follicles and 
corpora lutea during, 307 
Methanol, extracts of human plasma, PRL-
releasing activity in, problems with the 
bioassay of this activity, 199 
Metoclopramide 
clomiphene attenuation of the exaggerated 
PRL response to, in primary testicular 
failure, 289 
effect on the secretion and metabolism of 
aldosterone, 1014 
exaggerated PRL response to, in 1,2-di-
bromo-3-chloropropane-induced 
azoospermia, 38 
increased PRL release and milk secretion 
in Puerperium without stimulation of 
T S H and thyroid hormone secretion 
after administration of, 436 
PRL, PRA, and aldosterone responses to, 
suppression by dopamine infusion, 
1078 
Milk, human, L R H levels in, 826 
Mineralocorticoid, response to low dose 
ACTH infusion, 440 
Monocyte, insulin receptors of, in infants of 
strictly controlled diabetic mothers, 
473 
"mTc-methylene diphosphonate, effect of GH 
on metaphyseal uptake of, 1162 
Multiplication-stimulating activity, receptor, 
on human arterial and venous endothe-
lial cells, 814 
Myotonic dystrophy, hyperglucagonemia in, 
790 
Nelson's syndrome, subclinical infarction of 
pituitary adenoma in patients with, 95 
Nephrotic syndrome, vitamin D metabolites 
and calcium metabolism in patients 
with, 116 
Neurophysin, stimulation with estrogen, cor-
relation with oxytocin in human 
plasma, 988 
Neurotensin, production by pancreatic tu-
mors, 820 
Nonsuppressible insulin-like activity 
(NSILA), in thalassemia major, possi-
ble mechanism for deficiency of, 393 
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Nonthyroidal illness, estimates of free T 4 in, 
comparison of eight methods, 1073 
Nucleotide, gyanyl, -amplified renal adenylate 
cyclase assay, measurement of endog-
enous biologically active human PTH 
by, 840 
Obesity 
of the Prader-Willi syndrome, blunted pan-
creatic polypeptide responses in chil-
dren with, 1264 
role in polycystic ovary syndrome, 1242 
Opiate, endogenous, moderation of pulsatile 
LH release by, 583 
Opioid, control of L H in different pathophys-
iological states, 1260 
Osteoporosis, postmenopausal, 3-yr changes 
in the bone mineral mass of women 
with, based on neutron activation anal-
ysis of the central third of the skeleton, 
751 
Ovarian cycle 
effects of A9-tetrahydrocannabinol in rhesus 
monkeys during the follicular phase of, 
50 
in primates, suppression of FSH-dependent 
folliculogenesis during, 451 
Ovary 
changes during the menstrual cycle in the 
enzyme activities related to steroido-
genesis in, 994 
control of preovulatory follicular estrogen 
biosynthesis in, 847 
hilus cell tumors of, steroid secretion by, 
779 
insufficiency of, autoantibodies in patients 
with, 1137 
L H receptors in follicles of, during the men-
strual cycle and pregnancy, 307 
polycystic, role of obesity in the syndrome 
of, 1246 
polycystic disease of, elevations in unbound 
serum estradiol as a possible mecha-
nism for inappropriate gonadotropin 
secretion in women with, 156 
Ovulation, induction in a true hermaphrodite 
with male phenotype, 1257 
Oxytocin 
in human plasma, correlation with neuro-
physin stimulation with estrogen, 988 
release in women during lactation, 678 
Pancreas 
malignant somatostatinoma of, clinical fea-
tures and metabolic studies, 886 
secretion of immunoreactive somatostatin 
by, 589 
tumor of, neurotensin production by, 820 
Pancreatic polypeptide 
antibodies to, in insulin-treated diabetics, 
948 
blunted responses in children with the obe-
sity of the Prader-Willi syndrome, 1264 
decreased plasma levels in pregnancy, 605 
Parathyroid gland 
human fetal, immunocytological evidence 
for PTH in, 513 
hyperfunctioning, altered adenylate cyclase 
kinetics in, 499 
imaging after intraarterial injections of 
[75Se]selenomethionine, 835 
relationship of cAMP accumulation to PTH 
release in dispersed cells from patho-
logical tissue of, 961 
Parathyroid hormone (PTH) 
deficient P R L response to, in hypocalcemic 
and normocalcemic pseudohypopara-
thyroidism, 1099 
endogenous biologically active human, 
measurement by a gyanyl nucleotide-
amplified renal adenylate cyclase as-
say, 840 
in human fetal parathyroid glands, immu-
nocytological evidence for, 513 
release in dispersed cells from pathological 
human parathyroid tissue, relationship 
of cAMP accumulation to, 961 
secretion in normal man and in primary 
hyperparathyroidism, role of histamine 
H2 receptors, 122 
Peptide 
ß-endorphin-immunoreactive, in human se-
men, 586 
pro-opiomelanocortin-derived, secretion by 
a pituitary adenoma from a patient 
with Cushing's disease, 350 
Phenobarbital, neonatal treatment with, ef-
fect on testicular and adrenal functions 
and steroid binding in plasma in in-
fancy, 103 
Phosphate 
effect of calcitriol on renal handling of, in 
patients with X-linked hypophospha-
temia, 463 
effect of calcitriol on serum levels of, in 
patients with X-linked hypophospha-
temia, 463 
Piperidine, enhanced sleep-related and insu-
lin-induced GH secretion caused by, 
evidence for a cholinergic secretory 
mechanism, 409 
Pituitary, anterior, hormones of, plasma levels 
in women during lactation, 678 
Pituitary gland 
adenoma of, from a patient with Cushing's 
disease, secretion pattern of pro-opi-
omelanocortin-derived peptides by, 
350 
-adrenal periodicity, effects of jet lag on, 
628 
chromophobe adenoma of, secretion of L H 
and a-subunit by, 692 
delivery of 17/?-estradiol to, in rhesus mon-
keys, effect on gonadotropin secretion, 
1 
desensitization of with a long-acting L R H 
agonist, use in treatment of idiopathic 
precocius puberty, 370 
diseased, GH secretory status as a deter-
minant of the T S H response to T R H 
in euthyroid patients with, 324 
diseases of, plasma pituitary hormone re-
sponses to the synthetic enkephalin an-
alog (FK 33-824) in patients with, 263 
effect of human ^-endorphin on hormone 
release by, 1179 
fetal, the major immunoreactive aMSH-
like substance in, 319 
gonadotropins of, secretion in postmeno-
pausal females, GnRH down-regula-
tion of, 171 
hypofunction of, in children and adoles-
cents with central nervous system ger-
minomas, 9 
impact of euglycemia and hyperglycemia on 
stimulated release of hormones of, in 
insulin-dependent diabetics, 1230 
objectively recorded hot flushes in patients 
with insufficiency of, 684 
positive feedback of estrogen in L H - and 
a-subunit-secreting tumor of, 692 
predictors of the outcome of transsphenoi-
dal surgery for PRL-secreting adeno-
mas of, 785 
PRL-secreting adenomas of, increased gon-
adotroph responsivity in hyperprolac-
tinemic women with, 1171 
silent apoplexy of, subclinical infarction of 
an ACTH-producing pituitary ade-
noma, 95 
subclinical infarction of an ACTH-produc-
ing adenoma of, 95 
tumor of, in Cushing's disease, effects of 
lysine vasopressin, rat median emi-
nence extracts, T R H , and L R H on con-
comitant secretion of ACTH, ^-endor-
phin, and y-melanotropin from per-
fused cells of, 42 
Pituitary-gonadal axis, enhanced activity in 
premature human infants, 235 
Pituitary-testicular axis, in Oligospermie men, 
effects of A^testolactone on, 897 
Placenta 
human term, purification and immunohis-
tochemical localization of relaxin in, 79 
relaxin purification from basal plates of, 601 
Plasma, T4-binding globulin levels in, evi-
dence for microheterogeneity of, 657 
Platelet growth factor, in human GH-deficient 
patients, 128 
Polycystic ovary syndrome 
increased L H sensitivity to dopamine inhi-
bition in, 231 
role of obesity in, 1246 
Polyglandular failure syndrome, disordered 
immune function in patients with, 284 
Potassium, potency in regulating aldosterone 
in cardiac failure during Captopril ther-
apy, 1253 
Prader-Willi syndrome, blunted pancreatic 
polypeptide responses in children with 
the obesity of, 1264 
Pregnancy 
after prolonged pulsatile administration of 
L R H in a patient with clomiphene-re-
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Pregnancy (continued) 
sistant secondary amenorrhea, 882 
age-related changes in endogenous steroids 
of human fetal testis during, 98 
a separate mechanism of gonadotropin re-
covery after termination of, 545 
calcitriol treatment of hypoparathyroidism 
during, 810 
concentrations of aldosterone, corticoster-
one, 11-deoxycorticosterone, proges-
terone, 17-hydroxyprogesterone, 11-
deoxycortisol, Cortisol, and cortisone 
determined simultaneously in human 
amniotic fluid throughout, 385 
decreased plasma pancreatic polypeptide 
levels in, 605 
early, age-related changes in endogenous 
steroids of human fetal testis during, 
98 
insulin binding in, comparisons to the post-
partum luteal and follicular states, 937 
interrelationships between serum T 4 , T 3 , 
rT.3, and TSH in iodine-deficient 
women during, effects of iodine supple-
mentation, 671 
L H receptors in human corpora lutea dur-
ing, 307 
plasma ß-endorphin during, 74 
serum immunoreactive somatomedin levels 
at term in, 508 
transport of P R L by fetal membranes dur-
ing, 220 
Premarin, RIA of plasma equilin and estrone 
in postmenopausal women after the ad-
ministration of, 741 
Primate 
diurnal variation in cerebrospinal PRL con-
centrations in, 857 
regulation of changing ratios of nuclear es-
trone to estradiol binding in endome-
trium at implantation by hCG and pro-
gesterone during rescue of the corpus 
luteum of, 133 
rhesus monkey 
effects of A9-tetrahydrocannabinol on the 
follicular phase of the menstrual cycle 
in, 50 
luteolytic effect of D-Trp 6 -LRH in, 565 
studies on the site where estrogen inhibits 
gonadotropins in delivery of 17/?-estra-
diol to the hypothalamus and pituitary 
gland, 1 
suppression of FSH-dependent folliculo-
genesis during the ovarian cycle in, 451 
Progestagen 
-associated endometrial protein in the hu-
man decidua, immunocytochemical lo-
calization of, 1006 
-associated protein of human endometrium, 
RIA for, 1185 
Progesterone 
biosynthesis by human corpus luteum tis-
sue in organ culture, plasma lipopro-
tein regulation of, 875 
concentrations in human amniotic fluid 
throughout gestation, 385 
normal secretion in women with long-stand-
ing unexplained infertility, contrasting 
with abnormal FSH and L H patterns, 
1218 
receptor 
in human breast fibroadenomas, 1225 
modulation by natural and synthetic es-
trogens in human endometrial cells in 
primary tissue culture, 699 
regulation of the changing ratios of nuclear 
estrone to estradiol binding in endo-
metrium at implantation by, during 
rescue of the primate corpus luteum, 
133 
Progestin, receptor, concentrations in the en-
dometrium of postmenopausal women 
on estrogen replacement therapy, 
cyclic clomiphene citrate-induced low-
ering of, 345 
Prolactin (PRL) 
altered dopaminergic modulation of secre-
tion of, in pseudohypoparathyroidism, 
914 
concentrations in the cerebrospinal fluid of 
the rhesus monkey, diurnal variation 
in, 857 
deficient response to PTH in hypocalcemic 
and normocalcemic pseudohypopara-
thyroidism, 1099 
effect of exogenous ß-endorphin on pitui-
tary release of, 1179 
effect of histamine and HI and H2 receptors 
on the release of, sex differences and 
the role of stress, 924 
exaggerated response to T R H and metoclo-
pramide in l,2-dibromo-3-chloropro-
pane-induced azoospermia, 38 
exaggerated response to T R H and metoclo-
pramide occurring in primary testicular 
failure, clomiphene attenuation of, 289 
hyperprolactinemia, composition of breast 
fluid of a man with, 581 
L R F agonist-induced pulsatile release of, 
934 
metoclopramide-induced increase in release 
of, in Puerperium, without stimulation 
of TSH and thyroid hormone secretion, 
436 
plasma levels 
relationship of the diurnal rhythm of 
plasma immunoreactive ^-endorphin 
to, 942 
responses to the synthetic enkephalin an-
alog (FK 33-824) in normal subjects 
and patients with pituitary diseases, 
263 
response to changes in ambient temper-
ature and humidity, 279 
response to arginine infusions in hypothy-
roid patients, effect of T 3 or T R H on, 
86 
response to exercise after fat- and carbo-
hydrate-enriched diets, 56 
response to insulin-induced hypoglycemia, 
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effect of dopaminergic blockade on, 807 
response to T R H during R E M and slow 
wave sleep, 975 
response to T R H in hypogonadal and nor-
mal men, relationship of androgen to, 
173 
-secreting adenomas, cure of hypogonadism 
in men after removal of, 91 
-secreting pituitary adenomas, increased 
gonadotroph responsivity in hyperpro-
lactinemic women with, 1171 
-secreting pituitary adenoma, predictors of 
the outcome of transsphenoidal sur-
gery for, 785 
secretion in children, effect of a-bromoer-
gocriptine on, 314 
serum levels 
after chest wall surgery, elevated levels 
after mastectomy, 148 
in fullterm and premature infants, 235 
temporal relationship of decreased serum 
somatomedin C concentrations during 
sleep to nocturnal surges of, 399 
transport by human fetal membranes, 220 
Prolactin-releasing activity, problems with 
the bioassay of this activity in metha-
nol extracts of human plasma, 199 
Pro-opiomelanocortin, -derived peptides, se-
cretion by a pituitary adenoma from a 
patient with Cushing's disease, 350 
Proopiomelanocortin, N-terminal portion of, 
effect on aldosterone release by human 
adrenal adenoma in vitro, 1053 
Propylthiouracil, metabolism of in normal and 
hyperthyroid subjects, studies of using 
a newly developed RIA, 204 
Protein 
progestagen-associated, of human endome-
trium, RIA for, 1185 
progestagen-associated endometrial, im-
munocytochemical localization in the 
human decidua of, 1006 
Pseudohypoparathyroidism 
altered dopaminergic modulation of PRL 
and aldosterone secretion in, 914 
hypocalcemic, deficient P R L response to 
PTH in, 1099 
normocalcemic, deficient P R L response to 
P T H in, 1099 
Puberty 
correlation with urinary excretion of im-
munoreactive LRH, 1150 
idiopathic precocious, use of pituitary de-
sensitization with a long-acting L R H 
agonist in treatment of, 370 
Radioimmunoassay (RIA), oxytocin, mea-
surement in human plasma, correlation 
with neurophysin and stimulation with 
estrogen, 988 
Receptor(s) 
a-adrenergic, in human adipocyte mem-
branes, direct determination by [3H]-
yohimbine binding, 709 
androgen 
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in human skin cytosol, 338 
ontogeny in human foreskin, 919 
estradiol 
influence of endometrial 17ß-hydroxyste-
roid dehydrogenase activity on the 
binding of estradiol to, 252 
in human breast fibroadenomas, 1225 
estrogen, concentrations in the endome-
trium of postmenopausal women on es-
trogen replacement therapy, cyclic 
clomiphene citrate-induced lowering 
of, 345 
histamine H 2 , role in PTH secretion in nor-
mal man and in primary hyperparathy-
roidism, 122 
histamine (Hi and H 2), effect on PRL and 
L H release, sex differences and the role 
of stress, 924 
insulin 
changes in during oral contraceptive ad-
ministration, 29 
characterization of in cultured fibroblasts 
and erythrocytes, 17 
effect of glucocorticoids in vivo and in 
vitro on, 953 
on monocytes in infants of strictly con-
trolled diabetic mothers, 475 
insulin-binding on isolated erythrocytes, 
comparisons to that during the post-
partum, luteal, and follicular states, 937 
-insulin interaction in lipoatropic diabetes, 
heterogeneity of, 416 
LH, in human ovarian follicles and corpora 
lutea during the menstrual cycle and 
pregnancy, 307 
multiplication-stimulating activity, on hu-
man arterial and venous endothelial 
cells, 814 
progesterone 
in human breast fibroadenomas, 1225 
modulation by natural and synthetic es-
trogens in human endometrial cells in 
primary tissue culture, 699 
progestin, concentrations in the endome-
trium of postmenopausal women on es-
trogen replacement therapy, cyclic 
clomiphene citrate-induced lowering 
of, 345 
somatomedin, in vivo modulation of sites 
of, effects of GH treatment of hypopi-
tuitary children, 759 
TSH 
absence of in undifferentiated thyroid 
carcinoma, 23 
human, nonspecies-specific autoantibod-
ies to, 426 
in human thyroid tumors, 23 
soluble, in fat cells, interaction with thy-
roid-stimulating immunoglobulins, 665 
vasoactive intestinal peptide, characteriza-
tion in human colonic epithelial cells, 
715 
Relaxin 
in the human term placenta, purification 
and immunohistochemical localization 
in, 79 
purification from human placental basal 
plates, 601 
Renin 
levels in Liddle's syndrome, effect of triam-
terene and sodium intake on, 1027 
plasma activity (PRA), captopril-induced 
increase in, suppression by des-Asp1-
,Ileu8-angiotensin, 354 
Retinopathy, diabetic proliferative, associa-
tion with GH secretion response to 
T R H , 859 
Ribonucleic acid (RNA), messenger (mRNA), 
in a tumor, medullary thyroid carci-
noma identified by cell-free translation 
of, in a patient with a neck mass and 
the syndrome of ectopic ACTH, 572 
Sarcoidosis, increased 1,25-dihydroxychole-
calciferol as a cause of abnormal cal-
cium metabolism in, 494 
Schizophrenia, measurements of plasma de-
hydroepiandrosterone used to discrim-
inate between control subjects and pa-
tients with, 181 
Selenomethionine, 75Se-labeled, parathyroid 
imaging after intraarterial injections of, 
835 
Semen 
ß-endorphin6i-9i and other ß-endorphin-im-
munoreactive peptides in, 586 
inhibin levels in, in normal and infertile 
men, 796 
Sex, effect on insulin binding to erythrocytes, 
969 
Skeleton, isolated involvement in Cushing's 
syndrome, response to therapy, 1033 
Skin, human, androgen receptor in cytosol of, 
338 
Sleep 
decreased serum somatomedin C concen-
trations during, temporal relationship 
to the nocturnal surges of GH and 
PRL, 399 
rapid eye movement (REM), neuroendo-
crine responses to T R H during, 975 
-related GH secretion, enhancement by pi-
peridine, evidence for a cholinergic se-
cretory mechanism, 409 
relationship of the diurnal rhythm of 
plasma immunoreactive ß-endorphin 
to stages of, 942 
slow wave, neuroendocrine responses to 
T R H during, 975 
Sodium 
depletion of, decreased plasma and urinary 
dopamine levels with, 903 
effect on renin, aldosterone, and erythor-
cyte sodium transport in Liddle's syn-
drome of intake of, 1027 
transport in erythorcytes in Liddle's syn-
drome, effect of triamterene and so-
dium intake on, 1027 
Somatomedin 
acute response to GH, RIA vs. radiorecep-
tor assay, 616 
immunoreactive, serum levels in normal 
adults, pegnant women at term, chil-
dren at various ages, and children with 
constitutionally delayed growth, 508 
plasma levels, in transient neonatal diabe-
tes mellitus, 144 
plasma levels in children with hyperinsulin-
ism, 748 
receptor, in vivo modulation of sites of, 
effects of GH treatment of hypopitui-
tary children, 759 
Somatomedin C 
decreased serum levels during sleep, tem-
poral relationship to the nocturnal 
surges of GH and PRL, 399 
hyperprolactinemia in hypopituitarism as-
sociated with increased levels of, 731 
relationship between growth velocity and 
concentrations of, 622 
Somatostatin 
antibodies to, in insulin-treated diabetics, 
948 
clinical significance of altered insulin sen-
sitivity in diabetes mellitus assessed by 
infusion of, 982 
immunoreactive, in human pancreatic se-
cretion, 589 
-like components in tumors and plasma of 
a patient with a somatostatinoma, 66 
-like immunoreactive responses to insulin 
hypoglycemia and a mixed meal in 
healthy subjects and in noninsulin-de-
pendent maturity-onset diabetics, 330 
-like immunoreactivity, increased plasma 
and tumor levels of, in medullary thy-
roid carcinoma and small cell lung can-
cer, 187 
response to insulin-induced hypoglycemia, 
effect of truncal vagotomy, 823 
Somatostatinoma 
characterization of somatostatin-like com-
ponents in the tumors and plasma of a 
patient with, 66 
malignant, clinical features and metabolic 
studies, 886 
Spironolactone, plasma corticosteroid levels 
during the administration of, evidence 
for adrenal biosynthetic blockade, 1057 
Steroid (s) 
C-19, levels in fetal testis during early and 
midgestation, 98 
C-21, levels in fetal testis during early and 
midgestation, 98 
excretion in urine during suppression and 
stimulation of adrenals in the 17a-hy-
droxylase deficiency syndrome, 1039 
Stress 
-induced hyperglycemia in humans, syner-
gistic interactions among antiinsulin 
hormones in the pathogenesis of, 1235 
role in the effect of histamine and H i and 
H2 receptors on PRL and L H release, 
924 
Sulfonylurea, effect on gastric inhibitory poly-
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Sulfonylurea (continued) 
peptide hypersecretion in diabetes 
mellitus, 1002 
Testicular feminization syndrome, androgen 
receptors in skin cytosol of patients 
with, 338 
Testis 
fetal rat, in vitro inhibition of endometrial 
cancer growth by a secretory product 
of, 817 
function in infancy, effect of neonatal 
phenobarbital treatment on, 103 
human fetal, age-related changes during 
early and midpregnancy in endogenous 
steroids of, 98 
Leydig cell hyperplasia of, as a cause of 
famlial sexual precocity, 271 
primary failure of, clomiphene attenuation 
of the exaggerated P R L response to 
T R H and metoclopramide occurring 
in, 289 
seminal plasma of, inhibin levels in, in nor-
mal and infertile men, 796 
stimulation of cAMP and sex steroids in the 
spermatic venous blood after hCG in-
jection into, 688 
Al-Testolactone, effects on the pituitary-tes-
ticular axis in Oligospermie men, 897 
Testosterone 
-estradiol binding interactions under phys-
iological conditions, 868 
physiologically free circulating levels of, 
during exposure to levonorgestrel, 138 
serum levels, in fullterm and premature in-
fants, 235 
Testosterone-estradiol-binding globulin, es-
tradiol-testosterone binding interac-
tions with, free plasma estradiol under 
physiological conditions, 868 
Tetrahydroaldosterone, urinary excretion in 
white and black normal subjects and 
hypertensive patients, 214 
A9-Tetrahydrocannabinol, effects on the fol-
licular phase of the menstrual cycle in 
the rhesus monkey, 50 
Thalassemia major, possible mechanism for 
deficiency of NSILA in, 393 
Thyroglobulin, serum levels in the newborn, 
364 
Thyroglobulin - antithyroglobulin immune 
complex, circulating, in thyroid dis-
eases, detection of using enzyme-linked 
immunoassays, 239 
Thyroid gland 
carcinoma of, undifferentiated, absence of 
high affinity receptor and loss of TSH 
responsiveness in, 23 
characterization of major forms of calci-
tonin in tissue of, 1090 
diseases of, circulating thyroglobulin-anti-
thyroglobulin immune complex in, de-
tection of using enzyme-linked immu-
noassays, 239 
hemiagenesis of (hockey stick sign), a re-
view of the world literature and a re-
port of four cases, 247 
hemiaplasia of, with thyrotoxicosis, 152 
in patients with Graves' disease, enhance 
conversion of T 3 from T 4 in tissue from, 
1211 
in patients with painless thyroiditis, revers-
ible changes of the histological abnor-
malities of, 431 
medullary carcinoma of 
characterization of major forms of calci-
tonin in tissue and serum and tissue of 
patients with, 1090 
identified by cell-free translation of tu-
mor mRNA in a patient with a neck 
mass and the syndrome of ectopic 
ACTH, 572 
increased plasma and tumor somatosta-
tin-like immunoreactivity in, 187 
neoplastic, T 3 generation from T 4 in, 1211 
radioiodine uptake, early, patterns of 
change during Carbimazole treatment 
for Graves' disease and relationship to 
outcome, 1067 
-stimulating antibodies, time-related thy-
roid stimulation by, as measured by the 
cytochemical section bioassay, 483 
-stimulating immunoglobulin 
bioassay for, using cultured human thy-
roid cells, 1204 
development and evaluation of a method 
for partial purification of, 1113 
-stimulating immunoglobulins, interaction 
with soluble T S H receptors in fat cells, 
665 
time-related stimulation by TSH and thy-
roid-stimulating antibodies as mea-
sured by the cytochemical section 
bioassay, 483 
T S H receptors of, in Graves' disease, reac-
tion with ovine, bovine, and porcine 
TSH, 426 
Thyroiditis, painless, reversible changes of the 
histological abnormalities of the thy-
roid in patients with, 431 
Thyrotoxicosis 
hemiaplasia of the thyroid with, 152 
transient, reversible changes of the histo-
logical abnormalities of the thyroid in 
patients with, 431 
Thyrotropin-releasing hormone (TRH) 
clomiphene attenuation of the exaggerated 
PRL response to, in primary testicular 
failure, 289 
differential neuroendocrine responses to, 
during R E M and slow wave sleep, 975 
effect on pituitary hormone responses to 
arginine infusions in hypothyroid pa-
tients, 86 
effect on pituitary hormone release in dia-
betes mellitus, impact of euglycemia 
and hyperlycemia on, 1230 
effects on concomitant secretion of ACTH, 
ß-endorphin, and y-melanotropin from 
perfused pituitary tumor cells of Cush-
ing's disease, 42 
exaggerated PRL response to, in 1,2-di-
bromo-3-chloropropane-induced 
azoospermia, 38 
GH response to, in diabetes, 859 
GH secretory status as a determinant of the 
T S H response to, in euthyroid patients 
with hypothalamic-pituitary disease, 
324 
relationship of androgen to T S H and P R L 
responses to, in hypogonadal and nor-
mal men, 173 
responses of TSH, GH, and PRL to during 
R E M and slow wave sleep, 975 
Thyrotropin (TSH) 
effect of exogenous ß-endorphin on pitui-
tary release of, 1179 
falsely elevated serum levels in newborn 
infants, 62 
metoclopramide-induced increase in PRL 
release and mild secretion in Puerpe-
rium without stimulation of secretion 
of, 436 
receptor 
human, nonspecies-specific autoantibod-
ies to, in patients with Graves' disease, 
426 
soluble, in fat cells, interaction with thy-
roid-stimulating immunoglobulins, 665 
response to exercise after fat- and carbo-
hydrate-enriched diets, 56 
response to T R H during REM and slow 
wave sleep, 975 
response to T R H in hypogonadal and nor-
mal men, relationship of androgen to, 
173 
responsiveness to, in undifferentiated thy-
roid carcinoma, loss of, 23 
secretion in children, effect of a-bromoer-
gocriptine on, 314 
serum levels, interrelationships with T 4 , T 3 , 
and r T 3 in iodine-deficient pregnant 
women and their offspring, effects of 
iodine supplementation, 671 
time-related thyroid stimulation by, as 
measured by the cytochemical section 
bioassay, 483 
Thyrotropin (TSH) receptor, activity in hu-
man thyroid tumors, absence of high 
affinity receptor and loss of TSH re-
sponsiveness in undifferentiated thy-
roid carcinoma, 23 
Thyrotropin (TSS), response to T R H in eu-
thyroid patients with hypothalamic-pi-
tuitary disease, GH secretory status as 
a determinant of, 324 
Thyroxine-binding globulin, investigation of 
microheterogeneity, 657 
Thyroxine (T 4) 
free plasma levels, estimates in nonthyro-
idal illness, comparison of eight meth-
ods, 1073 
metoclopramide-induced increase in PRL 
release and milk secretion in Puerpe-
rium without stimulation of, 436 
response to exercise after fat- and carbo-
hydrate-enriched diets, 56 
serum levels, interrelationships with T 3 , 
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rT.3, and TSH in iodine-deficient preg-
nant women and their offspring, effects 
of iodine supplementation, 671 
T.3 generation in the human thyroid from, 
enhanced conversion in Graves' thy-
roid tissue, 1211 
T-Lymphocyte 
sensitization in Graves' and Hashimoto's 
diseases confirmed by an indirect mi-
gration inhibition factor test, 523 
subpopulations in Hashimoto's disease, 533 
suppressor deficiency of, in Graves' disease 
and Hashimoto's thyroiditis, 528 
Triamterene, effect on renin, aldosterone, and 
erythorcyte sodium transport in Lid-
dle's syndrome, 1027 
3,5',3'-Triiodothyronine (rT 3), serum levels, 
interrelationships with T 4 , T 3 , and 
TSH in iodine-deficient pregnant 
women and their offspring, effects of 
iodine supplementation, 671 
3,5,3'-Triiodothyronine (T 3) 
effect on pituitary hormone responses to 
arginine infusions in hypothyroid pa-
tients, 86 
generation from T 4 in the human thyroid, 
enhanced conversion in Graves' thy-
roid tissue, 1211 
metoclopramide-induced increase in PRL 
release and milk secretion in Puerpe-
rium without stimulation of secretion 
of, 436 
response to exercise after fat- and carbo-
hydrate-enriched diets, 56 
serum levels, interrelationships with T 4 , 
rT 3 , and T S H in iodine-deficient preg-
nant women and their offspring, effects 
of iodine supplementation, 671 
D-Trp(i-Luteinizing hormone-releasing hor-
mone, luteolytic effect in the rhesus 
monkey, 565 
Tumor 
mRNA of, medullary thyroid carcinoma 
identified by cell-free translation of, in 
a patient with a neck mass and the 
syndrome of ectopic ACTH, 572 
of the pancreas, neurotensin production by, 
820 
of the pituitary, in Cushing's disease, effects 
of lysine vasopressin, rat median emi-
nence extracts, TRH, and L R H on con-
comitant secretion of ACTH, ß-endor-
phin, and y-melanotropin from per-
fused cells of, 42 
ovarian hilus cell 
feminizing, steroid secretion by, 779 
masculinizing, steroid secretion by, 779 
somatostatinoma, characterization of so-
matostatin-like components in the tu-
mors and plasma of a patient with, 66 
Turner's syndrome, gonadal autoantibodies in 
patients with, 1137 
Vagotomy, truncal, effect on the somatostatin 
response to insulin-induced hypogly-
cemia, 823 
Vasoactive intestinal peptide, receptor, char-
acterization in human colonic epithe-
lial cells, 715 
Vasopressin, lysine, effects on concomitant 
secretion of ACTH, /^ -endorphin, and 
y-melanotropin from perfused pitui-
tary cells of Cushing's disease, 42 
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ABSTRACT. Preparation of T4-binding globulin (TBG) from 
human serum was performed using only two affinity chromatog-
raphy steps. Purity of the protein was demonstrated by a single 
band in overloaded disc and sodium dodecyl sulfate electropho-
resis, equimolar binding to T 4 , and linearity in sedimentation 
velocity run. The molecular weight was calculated to be 60,000 
± 3,000 dal tons (n — 3), the sedimentation coefficient was 3.95S, 
and the Stokes' radius was 37 A. The amino acid composition 
was found to be in good agreement with the calculations of other 
authors. By isoelectric focussing (IEF), pure TBG showed four 
main bands at pH 4.25, 4.35, 4.45, and 4.55 together with several 
fainter bands. The Af-acetylneuraminic acid (NANA) content of 
the four TBG bands isolated by preparative I E F was found to 
decrease from 10.2 mol NANA/moi TBG in the band at pH 4.25 
to 4.8 mol NANA/mol T B G in the band at pH 4.55. No signifi-
cant difference in the affinity constants of the T B G bands to T 4 
was found. The affinity constants for TBG ranged from 3.1 x 109 
to 7.2 X 109 M ~ \ Sequential kinetic desialylation of pure TBG 
resulted in a progressive tendency toward one major band at pH 
6.0. 
In native sera, microheterogeneity of TBG was detected after 
I E F on Polyacrylamide gel plates by immunofixation. The typical 
T B G patterns shown by pure T B G were also found in normal 
subjects. Characteristic deviations from this pattern were found 
in the sera of females during estrogen therapy or pregnancy, 
where there was a gradual increase in density of the band at pH 
4.25 and the appearance of an additional band at pH 4.15. In 
sera from patients with liver disease and elevated TBG levels, 
there was a fading of the acidic bands, whereas the more alkaline 
band at pH 4.55 was intensified. 
It is therefore proposed that microheterogeneity of TBG is 
caused by differences in NANA content and that variations of 
T B G patterns in native sera may reflect altered TBG synthesis 
or degradation. A genetically related microheterogeneity of T B G 
could not be demonstrated after examination of 800 sera, includ-
ing 2 families with quantitative TBG deficiency. (J Clin Endo-
crinol Metab 52: 657, 1981) 
SI N C E its discovery by Gordon et al. (1) in 1952, T 4 -binding globulin (TBG) has been a subject of inten-
sive research. When affinity chromatography was intro-
duced in 1969 by Marshall and Pensky (2) for purification 
of T B G , most of the physicochemical properties of the 
isolated protein could be confirmed (3-6). It is well es-
tablished that T B G binds equimolar quantities of T 4 and 
T 3 (5) with affinity constants of approximately 101 0 and 
109 M"1, respectively (7). T B G is an inter-a-globulin with 
a molecular weight of about 60,000 daltons and a carbo-
hydrate content of approximately 15% (8). It is composed 
of a single polypeptide chain (9) and four carbohydrate 
side chains (10). 
In 1973, Marshall et al. (11) first demonstrated a micro-
heterogeneity of isolated T B G by isoelectric focusing 
( IEF) , and this has been confirmed in our laboratories 
(5, 12, 13). The cause of this microheterogeneity is still 
controversial but is generally assumed to be produced by 
genetically determined variation in amino acid composi-
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tion of T B G (11) or by an irreversible transition of T B G 
near its isoelectric point (14). 
In this paper, we used a mild and rapid two-step 
purification procedure for T B G from human serum (13), 
a convenient method for detecting microheterogeneity 
patterns of T B G in native sera (12), and the preparative 
I E F technique to examine whether microheterogeneity 
of T B G is an artifact or might be explained by a differ-
ence in A^acetylneuraminic acid (NANA) content. Si-
multaneously, we screened for evidence of genetic varia-
tions in the T B G polypeptide chain. 
Materials and Methods 
Source of serum for TBG preparation and investigation of 
TBG microheterogeneity 
Human serum for isolation of T B G was obtained from 
healthy donors. Sera were pooled, frozen at once, and stored at 
—24 C. For examination of the microheterogeneity of T B G , 
individual sera were either stored at —24 C or used freshly. No 
preservatives were added to the sera. 
Preparation of TBG 
T 3 (600 mg; Henning, Berlin, Germany) were dissolved in 5 
ml 1 M NaOH, then 10 ml dimethyl-sulfoxide and 10 ml 0.1 M 
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borate buffer were added and the pH was adjusted to pH 10.0 
with 1 M HCl . [ 1 2 5 I ]T : l (1 ml; Hoechst AG, Frankfurt, Germany), 
purified by chromatography on alkaline Sephadex G-25 super-
fine (Pharmacia Fine Chemicals, Piscataway, NJ) , was then 
added for later calculation of bound T 3 . Moist Epoxy-activated 
Sepharose 6B (45 ml; Pharmacia) was then added to the T 3 
solution, and the gel suspension was gently shaken overnight at 
room temperature. After the gel was filtered and washed once 
with 0.01 M NaOH, it was shaken for an additional 4 h in 200 
ml 1 M ethanolamine to saturate free oxirane groups. After 
washing the gel alternatively with 1 liter 0.1 M acetate buffer, 
pH 4.0, and 1 liter 0.1 glycine NaOH buffer, pH 9.0, each 
containing 0.5 M NaCl, the T.r Sepharose 6B was counted for 
bound radioactivity. On the average, 150 mg T 3 were !inked to 
45 ml Epoxy-Sepharose 6B. 
T B G was extracted batchwise by gently shaking T.3-Epoxy-
Sepharose 6B in human serum (9 ml Epoxy-Sepharose/liter 
serum) diluted 2:1 with 0.1 M barbital buffer, pH 8.6, at room 
temperature for 1 h. After sedimentation of the Sepharose at 
4 C, the supernatant was decanted and the T.rSepharose was 
packed in a 2 x 15-cm column. Alternatively, T B G from 500 ml 
human serum or less was extracted quantitatively by affinity 
chromatography on a 45-ml T 3-Epoxy-Sepharose column. From 
here on, all steps were performed at 4 C and monitored at 280 
nm with Uvicord II (LKB-Produkter, Bromma, Sweden). Un-
specific bound proteins were eluted from the T,rEpoxy-Sepha-
rose 6B by extensive washing with 500 ml 0.1 M barbital buffer, 
pH 8.6, containing 1 M NaCl-500 ml 0.1 M Tris -HCl buffer, pH 
8.6, with 2 M NaCl-500 ml 0.05 M NaP04-buffer, pH 6.8, with 2 
M NaCl-500 ml 0.1 Tris-HCl-buffer, pH 8.6. 
T B G was then eluted specifically with 200 ml of a 10 mg/dl 
T 4 solution. T 4 (10 mg; Henning) was dissolved in 100 ml 0.1 M 
Tris-HCl buffer, pH 8.6, containing 0.1 g human serum albumin 
(HSA) purchased from Behring-Werke A G (Frankfurt, Ger-
many). The H S A had to be rechromatographed on Concana-
valin A (Con A)-Sepharose (Pharmacia) because of contami-
nation with other proteins. To remove endogenous H S A and 
the HSA from the T 4 solution, the T B G peak was applied to a 
2 X 50-cm Con A-Sepharose 4B column. After washing with 
300 ml 0.05 M Tris -HCl buffer, pH 7.4, containing 0.5 M NaCl, 
T B G was eluted with 0.03 M a-methyl-D-mannoside in 0.05 M 
Tris -HCl buffer, pH 7.4, containing 0.5 M NaCl. Desalting was 
performed by chromatography on a Sephadex G-25 coarse 
(Pharmacia) column, followed by dialysis. 
Characterization of TBG 
Disc electrophoresis was performed in 7.5% (wt/vol) or 5% 
(wt/vol) acrylamide and 0.24% (wt/vol) N,iV-methylene-bis-
acrylamide in Tris-glycine buffer, pH 8.9. Sodium dodecyl sul-
fate (SDS) electrophoresis was performed in 7.5% (wt/vol) 
acrylamide and 0.24% (wt/vol) A^N'-methylene-bisacrylamide 
in Tris-glycine buffer, pH 8.9. S D S electrophoresis was per-
formed in 7.5% (wt/vol) acrylamide and 0.24% (wt/vol) NtN'~ 
methylene-bisacrylamide in Tris-glycine buffer, pH 8.9, con-
taining 0.1 g/100 mg SDS. Slab gels of 0.5 x 15.5 cm were used. 
I E F on slab gels (0.5 x 17.5 cm) was carried out in 5.06% 
(wt/vol) acrylamide and 0.2% (wt/vol) iV,7V'-methylene-bisac-
rylamide containing 2.16% ampholine ( L K B and Pharmacia, 
respectively). 
For tracer studies, T B G , preincubated with [ 1 2 T ] T 4 or 
[ 1 2 5 I]T.i , was focussed in slab gel I E F , and then gels were cut in 
1-mm slices and counted for radioactivity. 
Staining of gels was performed with Coomassie blue R 250, 
bromphenol blue, or periodic acid Schiff's solution. The molec-
ular weight was determined by sedimentation equilibrium (15, 
16). 
Analytical aminoacid and hexosamine determinations were 
performed on an amino acid autoanalyzer (Durum D 100). 
Samples of T B G were hydrolyzed for 24 h at room temperature 
in 1 M HCl , with correction being made for amino acid loss 
during hydrolysis. The carbohydrate content was determined 
with anthron using glucose as the reference standard. 
The sialic acid content of T B G was determined by the 
thiobarbituric acid method (17) after hydrolysis in 0.1 N H 2 S O 4 
for 1 h at 80 C or cleavage by neuraminidase preparations from 
Clostridium perfringens, Vibrio cholerae, or influenza virus 
(Behring-Werke) (18-20). 
The T B G R I A was performed as described earlier (5). 
[ 1 2 5 I ] T B G was prepared with chloramine-T. Separation of an-
tibody-bound and free T B G was performed using a double 
antibody method. 
Methods for characterization of TBG microheterogeneity 
The incubation medium for enzymatic desialylation was 50 
(A 0.1 M acetate buffer (pH 5.6), 50 (x\ 50 mg/dl T B G , and 50 fa 
neuraminidase in different concentrations. For kinetic studies, 
incubation times varied from 2 min to 24 h. The enzymatic 
reaction was stopped by the addition of 50 fil 0.15 M glycine-
NaOH buffer, pH 11.0. Desialylation of T B G with the neura-
minidase preparation from Vibrio cholerae was performed in 
0.1 M acetate buffer, pH 5.6, containing 9 mg/ml NaCl and I 
mg/ml C a C l 2 . 
To examine nonspecific effects, either of the proteases pos-
sibly contaminating the neuraminidase preparations or of the 
acidic hydrolysis of T B G in the incubation medium, control 
experiments were performed by adding Aprotenin, a protease 
inhibitor (Trasylol, Bayer; 400 K I U / m l ) , or by incubation of 
T B G in the incubation medium without neuraminidase. 
I E F on flat bed Polyacrylamide gels (PAG plates) was carried 
out in 4.8% (wt/vol) acrylamide and 0.15% (wt/vol) N.AT'-meth-
ylene-bisacrylamide containing 2% (wt/vol) ampholine and 12.5 
g/dl sucrose. Plates of 235 X 105 X 1 mm were poured, and 
polymerization was catalyzed by riboflavin (3.3 X 10~5 g/dl). 
Samples were applied by filter paper (5 x 10 mm; Whatman, 
Inc., Clifton, NJ) placed on the P A G plates. For I E F , the L K B 
Multiphor 2117 chamber and the L K B power supply 2103 were 
used. Running conditions were limited power (20 watts), voltage 
(1000 V ) , and temperature (10 C) for 2 h. Focused protein bands 
were detected either by staining of the gel with Coomassie 
brilliant blue R 250 or immunofixation (21). Cellulose acetate 
strips (Millipore E S W P050 F0, Millipore Corp., Bedford, MA) 
were soaked with diluted T B G antiserum for 15 min, placed on 
the focussed P A G plates for 2 min, washed thoroughly in tap 
water overnight to remove nonprecipitated proteins, and then 
stained with Coomassie brilliant blue R 250. 
Densitometrie evaluation of the stained protein bands was 
M I C R O H E T E R O G E N E I T Y O F T B G 659 
carried out with Multiphorese Equipment (Fa. Vogel, Gießen, 
Germany). T B G antiserum was produced by immunization of 
rabbits with pure T B G . Monospecificity was demonstrated by 
Immunoelectrophoresis according to the methods of Grabar 
and Williams (22) and Clarke and Freeman (23). 
For preparative I E F , 4.0 g Sephadex G-75 fine (Ultrodex, 
L K B ) were mixed with 100 ml distilled water and 5 ml 40% (wt/ 
vol) ampholine (pH 3.5-5.0). In a trough (230 X 110 X 5 mm), 
gel was allowed to evaporate to exactly 73% (wt/vol) of its 
initial weight. Running conditions were limited power (8 watts), 
voltage (1000 V) , and temperature (10C) for 20 h. Then, the 
pH range from pH 4.0-4.7 (measured by a surface pH electrode, 
lot 403-30-80, Ingold, Germany) was cut off, the moist gel was 
diluted with distilled water (0.73:0.27, wt/vol), poured again in 
a clean trough, and then allowed to evaporate to exactly 73% 
(wt/vol) of the initial weight. Samples were dissolved in 3 ml 
1% (wt/vol) ampholines and applied. The single focussed T B G 
bands were harvested using L K B equipment and quantified by 
T B G RIA. 
Binding analyses of T 4 to T B G were carried out in microcells 
with Dianorm equilibrium dialysis apparatus (24, 25). One 
hundred microliters of T 4 standards (from 0.313-20 /xg/dl T 4 ) 
and 100 (A [ I 2 f t I ] T 4 (containing 1.2 jug/dl T 4 ) were filled into the 
first cell; 200 jul 0.025 mg/dl T B G were filled into the other cell. 
The T 4 content of T B G had been determined by R I A and 
amounted to 0.3 jtxg T 4/0.025 mg T B G . This T 4 concentration 
was taken into consideration when the affinity constant was 
calculated. All substances were dissolved in 0.1 M Tris -HCl 
buffer, pH 8.6. The cells were separated by a semipermeable 
membrane. Dialysis was allowed to take place overnight at 4 C; 
when equilibrium was reached, fractions were counted for ra-
dioactivity (correction was made for loss at the membranes). 
Association constants (K a ) and molar binding ratios were cal-
culated using a Scatchard plot (26). 
Results 
On the average, 60% of total serum T B G could be 
extracted in batches by the T,3-Epoxy-Sepharose 6B, and 
95% could be extracted by affinity chromatography. Dur-
ing the washing steps, a further purification was effected 
by varying hydrogen ion concentration and ionic 
strength, demonstrated by additional protein peaks in 
the eluted material. None of these protein peaks con-
tained immunoreactive T B G . After specific elution of 
T B G with the T 4-HSA-solution, only T B G and HSA 
were detected in disc electrophoresis. The H S A contam-
ination could be quantitatively removed by further affin-
ity chromatography on Con A-Sepharose (Fig. 1). The 
overall yield of pure T B G was about 40% by batchwise 
treatment and about 60% of total serum T B G (estimated 
by T B G RIA) by affinity chromatography. 
The prepared T B G gave one single band in overloaded 
disc electrophoresis at two Polyacrylamide concentra-
tions (7.5% and 5%). The molar binding ratio of T 4 to 
T B G , calculated from Scatchard plot, was 1:1. The purity 
of the T B G was further confirmed by a single band in 
overloaded S D S electrophoresis and by linearity in the 
sedimentation velocity run. The sedimentation coeffi-
cient was calculated to be 3.95S, the molecular weight 
was 60,000 ± 3,000 daltons (n = 3), and the Stokes* radius 
was 37 Ä. Analysis of amino acid composition was in 
good agreement with recently published data. In accord-
ance with Gershengorn et al. (14), 22 residues of gluco-
samine, but no galactosamine, were found. The total 
carbohydrate content was estimated to be 15%. 
Several T B G preparations from pooled human sera 
were found to show three distinct and (depending on the 
quantity of focussed T B G ) one to three less intensive 
bands in slab gel I E F in the pH area from pH 4.1-4.6. 
These bands coincided, regardless of the method of stain-
ing, with the radioactivity peaks obtained from the run 
of a T B G preincubated with [ 1 2 5 I ] T 4 or [ 1 2 5 I ] T 3 (Fig. 2). 
This indicated that all bands represented glycoproteins 
which bound thyroid hormones. 
The same microheterogeneity pattern of isolated T B G 
was obtained from P A G plate I E F either stained in the 
gel by Coomassie blue or identified by the immunofixa-
tion technique. Comparable T B G patterns, only detect-
able by immunofixation, were found in native sera from 
normal subjects. In addition, no change in T B G pattern 
in the same individuals was found when fresh or frozen 
serum was investigated. 
Kinetic in vitro desialylation studies with pure T B G 
performed using different neuraminidases showed similar 
results. After a short incubation time (2 min), microheter-
ogeneity increased immediately, showing new alkaline 
bands. Subsequently, dependent on incubation time, 
T B G bands migrated stepwise to more basic positions, 
finally reaching a characteristic end point. Most of the 
desialylated T B G focussed in a strong band at pH 6.0; 
additional faint bands were found at pH 5.4, 5.7, 6.2, and 
6.3 (Fig. 3). Treatment with all three neuraminidase 
preparations resulted in the same T B G pattern, differing 
only in their kinetics. 
Nonspecific effects of neuraminidases and incubation 
conditions could be excluded by control experiments. 
Radioimmunological determination of T B G with dif-
ferent degrees of desialylation documented the independ-
ence of immunoreactivity of T B G from its degree of 
sialylation. The recovery of different sialylated T B G in 
the T B G R I A was within the coefficient of variation. We 
found no significant loss of T B G when a T B G standard 
was incubated with neuraminidase and after desialylation 
was determined by T B G RIA. 
Simultaneous measurement of enzymatically removed 
NANA resulted in an increase parallel to incubation time 
and reached a maximum of 6 mol NANA/mol T B G at 
the end of desialylation. The total NANA content of 
T B G derived from hydrolysis with 0.1 N H 2 S 0 4 was 6.5 
mol NANA/mol T B G . 
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F I G . 1. Two-step purification of TBG 
from human serum. TBG was extracted 
by affinity chromatography on T 3 -
Epoxy-Sepharose 6B. Nonspecifically 
bound serum proteins were removed by 
washing with different buffer solutions. 
TBG was specifically eluted with 10 mg/ 
dl T4-HSA-0.1 M Tris-HCl buffer, pH 8.6. 
Endogenous HSA and HSA from the 
buffer were removed by a further affinity 
chromatography step using Con A-Seph-
arose 4B. The shaded area shows im-
munoreactive TBG (determined by 
RIA). 
T 3 - (12 carbon spacer) Sepharose 6B 
Specific elution of 
TBG with T 4/albumin 
Serum 
1M NaCt 
Tris - chloride 
01M pH 8 6 
0.13 mM \ . 0.1g/dl albumin 
Tris - chloride 
01 M pH 8 6 
Con A-Sepharose 4B 
Separation of 
albumin and TBG 
0D3Mrf-nwthy(-D-Mamoside 
Tris-chloride Tris-chloride 
0.05 M pH 74 0.05 M pH7.4 
F I G . 2. I E F on slab gels with a pH gradient from pH 3.5-5.0 (top). 
TBG was preincubated with [ 1 2 5 I ] T 4 or [ 1 2 5 I ]T 3 . Gels were either stained 
with bromphenol blue or cut in 1-mm slices and counted for radioactiv-
ity (bottom). 
Using preparative I E F , pure T B G derived from pooled 
serum of normal donors could be separated into four 
main constituents with pis at pH 4.25, 4.35, 4.45, and 
4.55. When pure T B G derived from females treated with 
estrogens was used, a fifth constituent with a pi of 4.15 
was obtained (Fig. 4). The single T B G bands were ex-
amined for NANA content and affinity constants to T 4 . 
The NANA content was 10.2 mol NANA/mol T B G 
(obtained from normal donors) for the most acidic T B G 
band (pi = 4.25), decreasing to 4.8 mol NANA/mol T B G 
for the most alkaline band (pi 4.55) (Table 1). The T B G 
band at pH 4.15 has not yet been examined for its NANA 
content because of its low concentration. The affinity 
constants were almost independent of the degree of sia-
lylation (3.1-7.2 X 109 M" 1). Even completely in vitro, 
desialylated T B G had a K a of 3.3 X 109 M" 1, which was 
not significantly different from those of isolated un-
treated T B G fractions. 
Using analytical flatbed I E F , followed by immunofix-
ation, about 800 native sera were examined for their 
patterns of microheterogeneity. All healthy examinees 
showed very similar I E F patterns, having the same pi 
and intensity as shown in preparative and slag gel I E F 
from pure T B G . 
In sera of patients suffering from thyroid diseases 
(hyperthyroidism, hypothyroidism, and euthyroid goi-
ter), significant variations of microheterogeneity patterns 
could not be detected. 
Two main groups of patients differing from this normal 
pattern were observed. The first group, suffering from 
liver diseases, revealed an intensified band at pH 4.55, 
with a relatively diminished band at pH 4.25 [Figs. 5 and 
6 (G and H)]. In a second group of patients with elevated 
estrogen levels, the band at pH 4.55 almost disappeared, 
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D e s i a l y l a t i o n o f i s o l a t e d T B G 
( C l o s t r i d i u m p e r f r i n g e n s ) 
* * * 5 . ^ ., 
i i r ' i I | l i I i | i 
540 540 180 30 60 1 5 15 5 2 2 2 -
incubation time ( min ) 
PH 
I-6 
F I G . 3. Sequential desialylation of pure 
TBG. Pure TBG (50 /ig) was incubated 
with different neuraminidase concentra-
tions from 0-100 mU/ml for 0-540 min 
in 0.1 M acetate buffer, pH 5.6. After I E F 
on PAG plates (pH gradient from 3.5-
10.0), T B G was detected by immunofix-
ation. 
I 1 1 1 1 I I I l I l I i 
100 100 100 20 20 4 4 4 2 1 -
neuraminidase ( mU / ml 
F I G . 4. Preparative I E F of pure TBG. I E F was performed on flatbed 
gel (Ultrodex, LKB) . TBG concentrations of the fractions were deter-
mined by TBG R I A ; the corresponding pH values were measured with 
a pH electrode. 
T A B L E 1. NANA content and affinity constants to T 4 of the single 
T B G constituents isolated by preparative I E F of pure T B G 
Pi 
NANA:TBG 
ratio 
(mol/mol) 
K a 
(x 109 M - 1 ) 
Isolated T B G 6.5 6.1 
Separated in 4.25 10.2 3.1 
4.35 7.2 5.9 
4.45 5.0 7.2 
4.55 4.8 5.0 
desialylated 6.2 — 3.3 
whereas the band at pH 4.25 was intensified. In sera from 
the latter group of subjects with higher T B G levels (3.5 
mg/dl), an additional band at pH 4.15 appeared [Fig. 6 
(F and I)] . 
These changes in microheterogeneity patterns were 
liver 
cirrhosis 
pregnancy 
normal control pH 4.55 435 A.15 
F I G . 5. Immunofixation of TBG after I E F on PAG plates (pH 3.5-5.0). 
The TBG pattern of a female suffering from liver cirrhosis is compared 
with those of a pregnant woman (28th week of pregnancy) and a normal 
control. 
shown to be variable in several women during pregnancy 
and 1 week after delivery. During pregnancy, the patterns 
changed parallel to the increase of T B G levels, as de-
scribed above [Figs. 6 (D-F) and 7]. One week after 
delivery, when T B G levels had not yet changed signifi-
cantly, the most acidic band had disappeared, whereas 
the band at pH 4.55 intensified again. 
The sera of members from two families with congenital 
T B G deficiency were examined, but no variation in the 
microheterogeneity pattern could be detected compared 
with that in normal subjects. In these families, an x-
autosomal pattern of inherited low serum immunoreac-
tive T B G levels (0.2-0.4 mg/dl) was found. 
Euthyroid healthy newborns at term had elevated 
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normal controls pregnancy liver c irrhosis 
O.D 
[536 nm 
pH A 55 4 15 415 4 55 4 35 4 V 4 55 4 35 4 15 
F I G . 6. Densitometrie evaluation [optical density (O.D), 536 nm] of 
some typical TBG patterns after I E F on PAG plates (pH 3.5-5.0), 
followed by immunofixation. 
pH 
-A. 55 
4.35 
4.15 
1 T 
F I G . 7. Immunofixation of TBG after I E F on PAG plates (pH 3.5-5.0). 
TBG patterns during the course of pregnancy from one individual are 
shown. TBG microheterogeneity is shown in the 4th (1), 16th (2), 28th 
(3), and 35th (4) weeks of pregnancy. 
serum T B G levels of 2.76 ± 0.5 mg/dl (n = 12) and 
normally distributed microheterogeneity bands, with the 
most alkaline one (pi = 4.55) slightly intensified. 
The sera of four 1- to 5-day-old premature newborns, 
two of whom were twins, however, revealed microheter-
ogeneity patterns not seen up to this point. In addition 
to the three main bands (pi 4.55, 4.45, and 4.35), there 
were faint bands close to the normal bands, giving a 
picture of double bands. Six months later when the T B G 
pattern of one of these infants was reinvestigated, it was 
found to be comparable to the patterns of euthyroid 
normal mature newborns (Fig. 8). 
Discussion 
Since the introduction of affinity chromatography for 
the T B G preparation from human serum by Marshall 
and Pensky (2) in 1969, various procedures for isolation 
of T B G have been reported, all requiring at least two 
further chromatographic steps, including ion exchange 
chromatography (4, 5). The authors have succeeded in 
establishing a rapid, mild, two-step T B G purification 
procedure using T 3-Epoxy-Sepharose 6B and Con A-
Sepharose 4B affinity chromatography. The overall yield 
of about 60% pure T B G by this preparation was approx-
imately 3 times the yield described by other authors (2-
5). A high yield of pure T B G was the requirement for 
further characterization of T B G microheterogeneity. 
Microheterogeneity of isolated T B G was first demon-
strated in slab gel I E F (11). That the observed micro-
heterogeneity was not related to the purification proce-
dure has been confirmed by examination of individual 
native sera. The microheterogeneity bands of isolated 
T B G coincided with radioactivity peaks in slab gel I E F 
after preincubation of serum with [ 1 2 T ] T 4 or [ 1 2T]T .3 and 
with the immunofixation precipitation lines of native sera 
after P A G plate I E F . To exclude artifacts in I E F , differ-
ent agents were used for polymerization of acrylamide 
(riboflavin and ammoniumpersulfate) and different com-
mercial ampholines (from L K B and Pharmacia) were 
used with different pH gradients and different modes of 
sample application (anodal and cathodal) either on slab 
gels or P A G plates. In each case, identical microhetero-
geneity patterns were seen. This was in contrast to the 
findings of Marshall et al. (11), who detected four bands 
PH 
-4.55 
-4.35 
-4.15 
1 T T 
F I G . 8. Immunofixation of TBG after I E F on PAGE plates (pH 3.5-
5.0). The TBG patterns of two premature 5-day-old newborns (1, 2) are 
shown; one of them was reinvestigated 6 months later (3). 
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when using ammonium persulfate for polymerization of 
acrylamide, but at least nine bands in the pH area from 
4.2-5.2 when using photopolymerization with riboflavin. 
These differences probably are related to the fact that 
we added samples to the unpolymerized gel suspension 
only after the polymerizing agent had been removed by 
a short prerun. 
During sequential desialylation studies of isolated 
T B G , we observed a change in the mobility of micro-
heterogeneity bands to alkaline pH, with subsequent 
reduction to one main band at pH 6.0 and several faint 
bands which remained in more alkaline and acidic posi-
tions even when the desialylation conditions were inten-
sified. Control experiments with a protease inhibitor 
(Aprotenin-Trasylol) or in simple buffer (without neur-
aminidase) excluded artifacts due to the desialylation 
treatment per se. Despite this, a single T B G band in I E F 
was never achieved by desialylation, leading us to the 
hypothesis that a variable NANA content could be the 
cause of the microheterogeneity observed in pure T B G 
preparations as well as in the individual native sera. The 
single isolated T B G bands differed from one another in 
sialic acid content. 
The results from the desialylation studies are in disa-
greement with those of Marshall et al. (11), whose desi-
alylation studies resulted in an alkaline displacement of 
the microheterogeneity pattern without any reduction in 
the number or intensity of the bands. To explain the 
nondisappearance of the faint bands after the desialyla-
tion procedure described here, it is supposed that the 
stability of the residual carbohydrate chains or of the 
whole molecule may be diminished after desialylation, so 
that the incubation in acetate buffer, pH 5.6, for several 
hours may cause mild hydrolysis of the carbohydrate 
residues. 
The total NANA content of pure T B G was found to 
be from 6.0-6.5 mol/mol T B G . Zinn et al (10) found 9 
mol NANA/mol T B G and believed that these were lo-
cated at the terminal groups of the four carbohydrate 
side chains. Since the different T B G bands found on 
isoelectric focussing contained amounts of NANA vary-
ing from 4-10 mol/mol T B G , the mean content of 6.5 
mol NANA/mol pure T B G found seems reasonable. Data 
for the NANA content of T B G found in the literature 
vary from 0-10 mol NANA/mol T B G . Since sialic acid is 
the most labile of any of the serum carbohydrates, the 
differences of NANA content in the literature may be 
due to variations in the methods of handling the serum, 
including collection and purification. 
As microheterogeneity of T B G was investigated using 
only isolated T B G from pooled serum, variations of in-
dividual T B G microheterogeneities have remained un-
detected until now. I E F on P A G plates, followed by 
immunofixation, is a simple and rapid method for inves-
tigating the individual T B G microheterogeneities in large 
numbers of different sera. Almost all sera, including those 
from individuals with inborn T B G deficiency or different 
thyroid diseases, revealed microheterogeneity patterns 
comparable with that of T B G prepared from pooled sera. 
Striking changes were found in states known to influ-
ence glycoprotein synthesis and degradation. The influ-
ence of elevated estrogens on liver protein synthesis, as 
occurs during pregnancy or estrogen therapy, resulted in 
the appearance of an additional T B G band with a pi of 
4.15 and a simultaneous reduction in the intensity of the 
band at pH 4.55. Sequential investigations in several 
women during pregnancy showed that this phenomenon 
paralleled the increase in the T B G level in serum. Glinoer 
et al. (27, 28) observed an estrogen-stimulated T B G 
production rate in rhesus monkeys 2.9 times normal and 
a degradation rate 0.9 times normal. The additional acid 
band observed in our investigations is interpreted as an 
expression of the increased production rate, with a more 
sialylated T B G circulating in serum. According to our 
findings, the degradation rate must also be increased, as 
demonstrated by the fading alkaline band representing 
the more desialylated T B G . 
Like other glycoproteins, T B G is assumed to be desi-
alylated by peripheral neuraminidases and then to be 
bound to receptors (for desialylated glycoproteins) on 
the liver cell membrane for further degradation (29-33). 
Marshall et al. (30) demonstrated that less T B G from 
the serum of patients with liver cirrhosis is bound to 
hepatocellular membranes in vitro than T B G from serum 
of healthy donors. It is assumed that the increase of 
alkaline bands of T B G from patients with liver cirrhosis 
and elevated T B G levels which we found using the im-
munofixation technique is an indication of reduced deg-
radation caused either by a reduction in the number of 
liver receptors for desialylated glycoproteins or a relative 
saturation of these receptors by other glycoproteins. 
The double band microheterogeneity seen in prema-
ture newborns was normalized 6 months after birth, 
indicating a change in T B G sialylation or glycosilation 
during maturation. In sera of healthy newborns at term, 
this double band configuration was not found. A higher 
degree of sialylation of glycoproteins in fetal liver as well 
as in primary liver cell carcinoma has been described 
(34); an altered sialylation of T B G in the premature liver 
resulting in these double configurated T B G bands is 
possible. However, since the distance between the bands 
is smaller than that observed by the removal of 1 mol 
NANA, an altered carbohydrate composition in this pre-
mature T B G other than sialic acid is possible and, there-
fore, worth further investigation. 
In the present study, affinity constants of the single 
T B G bands for T 4 were not found to differ from one 
another. Cheng et al. (35) also found a slightly diminished 
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affinity constant of deglycosilated T B G to T 4 . However, 
Marshall et al. (29) and Refetoff et al. (31) have reported 
that even completely in vitro desialylated T B G was not 
found to change its affinity constant to T 4 . From the 
clinical point of view, it is important to note that even 
marked changes in the microheterogeneity of T B G in 
different metabolic states do not affect the T 4 to T B G 
ratio (36). 
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